The Antibody Drug Conjugate Market is anticipated to grow at a CAGR of around 10% by 2035, according to a market research report by Roots Analysis

Antibody drug conjugates have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional cancer treatment options) of antibody-drug conjugates. Therefore, the increasing prevalence of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Further, in the past few years, several well-funded start-ups / small companies, offering antibody drug conjugate having advanced linkers and more potent warheads have been established. Additionally, FDA has been actively reviewing and approving ADC therapeutics for cancer. The rising incidence of cancer in the US will drive the adoption of antibody drug conjugates. As per the American Cancer Society, over 1.9 million cancer patients were estimated to be diagnosed in the US in 2022.

Antibody drug conjugates have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional cancer treatment options) of antibody-drug conjugates. Therefore, the increasing prevalence of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Further, in the past few years, several well-funded start-ups / small companies, offering antibody drug conjugate having advanced linkers and more potent warheads have been established. Additionally, FDA has been actively reviewing and approving ADC therapeutics for cancer. The rising incidence of cancer in the US will drive the adoption of antibody drug conjugates. As per the American Cancer Society, over 1.9 million cancer patients were estimated to be diagnosed in the US in 2022.

To order this 710+ page report, which features 285+ figures and 350+ tables, please visit our Antibody Drug Conjugate Market Report

Key Market Insights

For additional details, please visit https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html 

The financial opportunity within the antibody drug conjugate market has been analysed across the following segments:

The report features input from eminent industry stakeholders, according to whom upcoming generations of antibody drug conjugates are likely to garner significant interest among therapy developers and end users. The report features detailed transcripts of interviews and surveys held with the following experts:

The report also includes detailed profiles of key players (listed below) engaged in the development of antibody drug conjugates; each profile features a brief overview of the company, financial information (if available), details related to product portfolio, recent developments, and an informed future outlook.

Key Questions Answered

Table of Contents

To purchase a copy, please visit https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html 

You may also be interested in the following titles:

Contact:

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
gaurav.chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/the-antibody-drug-conjugate-market-is-anticipated-to-grow-at-a-cagr-of-around-10-by-2035-according-to-a-market-research-report-by-roots-analysis-301917107.html